Monitor the effective date of this S-3 and subsequent selling activity by the institutional holders listed (Sirenia, AIGH, Millennium, etc.). The massive overhang (~144% of float) will likely pressure the stock. Watch for any positive clinical catalyst from the QRX003 Netherton Syndrome trial that could trigger early warrant exercise and reduce the overhang.
Price Chart
Executive Summary
Quoin Pharmaceuticals filed an S-3 registration statement to register 9,371,895 ADSs for resale by selling shareholders from its August 2026 private placement. The company will not receive proceeds from resales but could receive up to ~$19.1 million if all Ordinary Warrants are exercised for cash. The filing highlights massive potential dilution — the newly registered ADSs represent ~144.2% of currently outstanding ADSs — and the company's pre-revenue status with a going-concern audit opinion.
Key Financial Metrics
Key Facts
- S-3 registers 9,371,895 ADSs for resale by selling shareholders from an August 27, 2026 private placement that closed on August 31, 2026 for gross proceeds of ~$30.8 million.
- The number of ADSs covered by this prospectus not currently outstanding (3,802,130 Pre-Funded ADSs + 3,123,965 Ordinary Warrant ADSs) represents approximately 144.2% of the 4,804,161 ADSs outstanding as of September 16, 2026.
- Company will not receive any proceeds from resales but could receive up to ~$19.1 million (less placement agent fees) if all Ordinary Warrants are exercised for cash at $6.10 per ADS.
- Ordinary Warrants have a five-year term and are exercisable until the earlier of five years from closing or 30 days after announcement that the primary endpoint has been met in the Netherton Syndrome trial CL-QRX003-004.
- The company is pre-revenue with no products commercialized and has a going-concern explanatory paragraph in its audited financial statements.
- Insider participants (CEO, COO, CFO, and a director) purchased 57,370 Offered ADSs and 28,865 Ordinary Warrants for ~$280,000 in the private placement.
- The company is subject to a 90-day equity financing restriction from the closing date and must hold a shareholder meeting within 90 days to seek approval to increase beneficial ownership limits from 4.99% to 9.99%.
- Lock-up agreements with directors and officers restrict sales until the later of 90 days after closing or the effective date of the registration statement.
Financial Impact
Potential dilution of ~144.2% of current ADSs outstanding; potential cash inflow of up to ~$19.1M from warrant exercise; company has no revenue and a going-concern opinion.
Risk Factors
- Massive dilution risk: newly registered ADSs represent ~144.2% of current outstanding ADSs, which could severely depress the stock price upon resale.
- Pre-revenue clinical-stage biotech with a going-concern opinion — the company will likely need additional capital beyond the warrant exercise proceeds to fund operations.
- Ordinary Warrants have a cashless exercise feature if no effective registration statement is available after six months, which could lead to further dilution without cash proceeds.
- Shareholder vote to increase beneficial ownership limits to 9.99% could concentrate voting power among a few large holders.
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001104659-26-108970 |
| Document: tm2625587d1_ex-filingfees.htm | 0001104659-26-108970 |
| Document: tm2625587d1_ex5-1.htm | 0001104659-26-108970 |
| Document: tm2625587d1_ex23-2.htm | 0001104659-26-108970 |
| Document: tm2625587d1_ex23-1.htm | 0001104659-26-108970 |
| Document: 0001104659-26-108970-index-headers.html | 0001104659-26-108970 |
| Document: 0001104659-26-108970-index.html | 0001104659-26-108970 |
| Document: 0001104659-26-108970.txt | 0001104659-26-108970 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $4.04 | awaiting T+5 | — | $4.01 (−0.74%) |
Oct 19, 2026 7d ago | ANALYST-UPGRADE | $3.98 $4.01 | ▲ +0.75% | ▲ +0.90% | $4.01 (+0.75%) |
Oct 14, 2026 13d ago | 8-K | $4.10 $3.99 | ▼ −2.68% | ▼ −3.14% | $4.01 (−2.20%) |
Oct 12, 2026 15d ago | ANALYST-UPGRADE | $4.36 $3.98 | ▼ −8.72% | ▼ −6.81% | $4.01 (−8.03%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.55 $4.03 | ▲ +11.43% | ▲ +11.15% | $4.01 (+11.87%) |
Oct 2, 2026 24d ago | DEF 14A | $4.56 $4.36 | ▼ −4.28% | ▼ −4.70% | $4.01 (−11.96%) |
Sep 28, 2026 29d ago | EFFECT | $5.26 $4.56 | ▲ +13.40% | ▲ +14.61% | $4.01 (+23.76%) |
Sep 22, 2026 4w ago | Press Release | $7.01 $4.88 | ▼ −30.39% | ▼ −29.20% | $4.01 (−42.80%) |
Sep 18, 2026 5w ago | S-3 | $6.90 $5.26 | ▲ +23.77% | ▲ +22.75% | $4.01 (+41.88%) |
Sep 1, 2026 7w ago | Insider Cluster | $6.74 $6.90 | ▲ +2.37% | ▲ +3.33% | $4.01 (−40.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers